🕵️ Enliven Therapeutics, Inc. ($ELVN)
SEC insider & ownership activity, last 12 months · CIK 1672619 · every row links its SEC filing
Over the last 12 months insiders sold $76.5M with no open-market buying against it. Orbimed Advisors LLC sold $51.7M (Jun). Orbimed Advisors LLC trimmed 10.9% → 9.5%; Orbimed Capital GP VII LLC trimmed 10.6% → 9.2%. No red-flag 8-Ks in the window.
🚨 9 signals active —
planned-vs-executed verdicts, pre-event flags, and cluster context live in the
API and the
alerts bot.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 9 sellers, $76.5M (79 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 0 | – | 6 | $51.7M | Jun 22, 2026 |
| Mika K. Derynck | 0 | – | 1 | $9.6M | Aug 4, 2026 |
| Collins Helen Louise | 0 | – | 21 | $5.1M | Aug 17, 2026 |
| Joseph P. Lyssikatos | 0 | – | 15 | $5.0M | Feb 6, 2026 |
| Patel Anish | 0 | – | 7 | $1.7M | Jan 9, 2026 |
| Hohl Benjamin | 0 | – | 12 | $1.3M | Aug 17, 2026 |
| Kunkel Lori Anne | 0 | – | 5 | $850K | Jul 6, 2026 |
| Kintz Samuel | 0 | – | 6 | $785K | Nov 17, 2025 |
| Richard A. Heyman | 0 | – | 6 | $413K | Feb 17, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| FMR LLC | 15.0% | 13G | Aug 6, 2026 | filing ↗ | |
| Abigail P. Johnson | 15.0% | 13G | Aug 6, 2026 | filing ↗ | |
| Orbimed Advisors LLC | 9.5% | 13D | Jun 22, 2026 | filing ↗ | |
| Orbimed Capital GP VII LLC | 9.2% | 13D | Jun 22, 2026 | filing ↗ | |
| Polar Capital Holdings PLC | 8.5% | 13G | Jun 22, 2026 | filing ↗ | |
| Polar Capital LLP | 8.5% | 13G | Jun 22, 2026 | filing ↗ | |
| Polar Capital Funds PLC - Biotechnology Fund | 8.5% | 13G | Jun 22, 2026 | filing ↗ | |
| Commodore Capital LP | 7.7% | 13G | May 15, 2026 | filing ↗ | |
| Commodore Capital Master LP | 7.7% | 13G | May 15, 2026 | filing ↗ | |
| Robert Egen Atkinson | 7.7% | 13G | May 15, 2026 | filing ↗ | |
| Michael Kramarz | 7.7% | 13G | May 15, 2026 | filing ↗ | |
| Tomas Kiselak | 6.3% | 13G | Aug 14, 2025 | filing ↗ | |
| Vestal Point Capital, LP | 5.4% | 13G | May 15, 2026 | filing ↗ | |
| Ryan Wilder | 5.4% | 13G | May 15, 2026 | filing ↗ | |
| BlackRock, Inc. | 5.1% | 13G | Jul 17, 2025 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Mika K. Derynck | $9.2M | Aug 4, 2026 | filing ↗ |
| Collins Helen Louise | $763K | Jul 17, 2026 | filing ↗ |
| OrbiMed Genesis Master Fund, L.P. | $1.1M | Jun 22, 2026 | filing ↗ |
| OrbiMed Genesis Master Fund, L.P. | $68K | Jun 22, 2026 | filing ↗ |
| OrbiMed Private Investments VII, LP | $36.2M | Jun 22, 2026 | filing ↗ |
| OrbiMed Private Investments VII, LP | $2.1M | Jun 22, 2026 | filing ↗ |
| The Biotech Growth Trust PLC | $1.4M | Jun 22, 2026 | filing ↗ |
| The Biotech Growth Trust PLC | $80K | Jun 22, 2026 | filing ↗ |
| Hohl Benjamin | $768K | Jun 17, 2026 | filing ↗ |
| The Biotech Growth Trust PLC | $434K | Jun 15, 2026 | filing ↗ |
| OrbiMed Private Investments VII, LP | $11.5M | Jun 15, 2026 | filing ↗ |
| OrbiMed Genesis Master Fund, L.P. | $385K | Jun 15, 2026 | filing ↗ |
| Kunkel Lori Anne | $710K | Jun 5, 2026 | filing ↗ |
| Collins Helen Louise | $620K | May 18, 2026 | filing ↗ |
| Joseph P. Lyssikatos | $1.1M | Apr 30, 2026 | filing ↗ |
| Joseph P. Lyssikatos | $915K | Mar 31, 2026 | filing ↗ |
| Andrew Phillips | $1.0M | Mar 31, 2026 | filing ↗ |
| Collins Helen Louise | $1.4M | Mar 25, 2026 | filing ↗ |
| Patel Anish | $3.1M | Mar 24, 2026 | filing ↗ |
| Collins Helen Louise | $1.3M | Mar 9, 2026 | filing ↗ |
| Hohl Benjamin | $293K | Mar 6, 2026 | filing ↗ |
| Joseph P. Lyssikatos | $2.0M | Feb 18, 2026 | filing ↗ |
| Kintz Samuel | $2.0M | Feb 17, 2026 | filing ↗ |
| Richard A. Heyman | $33K | Feb 17, 2026 | filing ↗ |
| Collins Helen Louise | $1.2M | Feb 17, 2026 | filing ↗ |
| Andrew Phillips | $612K | Feb 2, 2026 | filing ↗ |
| Richard A. Heyman | $33K | Jan 20, 2026 | filing ↗ |
| Joseph P. Lyssikatos | $1.7M | Jan 9, 2026 | filing ↗ |
| Kintz Samuel | $1.7M | Jan 9, 2026 | filing ↗ |
| Patel Anish | $1.1M | Jan 9, 2026 | filing ↗ |
| Kintz Samuel | $1.3M | Jan 8, 2026 | filing ↗ |
| Joseph P. Lyssikatos | $1.3M | Jan 8, 2026 | filing ↗ |
| Richard A. Heyman | $25K | Jan 8, 2026 | filing ↗ |
| Richard A. Heyman | $190K | Jan 8, 2026 | filing ↗ |
| Joseph P. Lyssikatos | $83K | Dec 19, 2025 | filing ↗ |
| Kintz Samuel | $85K | Dec 17, 2025 | filing ↗ |
| Patel Anish | $145K | Dec 8, 2025 | filing ↗ |
| Joseph P. Lyssikatos | $282K | Nov 19, 2025 | filing ↗ |
| Kintz Samuel | $276K | Nov 17, 2025 | filing ↗ |
| Joseph P. Lyssikatos | $268K | Oct 20, 2025 | filing ↗ |
| Kintz Samuel | $272K | Oct 17, 2025 | filing ↗ |
| Hohl Benjamin | $90K | Sep 29, 2025 | filing ↗ |
| Joseph P. Lyssikatos | $249K | Sep 19, 2025 | filing ↗ |
| Kintz Samuel | $230K | Sep 17, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Earnings (2.02) | Aug 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 5, 2026 | filing ↗ |
| Material agreement (1.01) | Jun 11, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 11, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 11, 2026 | filing ↗ |
| Other events (8.01) | Jun 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 11, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Jun 9, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 9, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 9, 2026 | filing ↗ |
| Earnings (2.02) | May 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 7, 2026 | filing ↗ |
| Earnings (2.02) | Mar 3, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 3, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jan 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 6, 2026 | filing ↗ |
| Officer/director changes (5.02) | Dec 9, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Dec 9, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 9, 2025 | filing ↗ |
| Earnings (2.02) | Nov 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 12, 2025 | filing ↗ |
| Earnings (2.02) | Nov 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 12, 2025 | filing ↗ |